THIS TASK ORDER IS FOR THE PROTEOMIC CHARACTERIZATION LABORATORY.

此任务单适用于蛋白质组表征实验室。

• 批准号: 10502629
• 负责人: WILLIAM BOCIK
• 金额: $ 639.13万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-25 至 2026-09-24
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10502629
• 关键词: Affinity; Aftercare; Antibodies; Benchmarking; Biological; Biological Assay; Biomedical Research; Biopsy Specimen; Clinical; Clinical Trials Network; Communities; Competence; Complex Mixtures; Core Biopsy; Custom; Investigational Therapies; Laboratories; Liquid substance; Malignant Neoplasms; Mass Spectrum Analysis; Measurement; Methods; Modeling; Molecular; National Cancer Institute; Patients; Peptides; Pharmacodynamics; Phosphorylation; Post-Translational Protein Processing; Proteins; Proteome; Proteomics; Reagent; Research Institute; Specimen; Standardization; Tissues; Translating; anticancer research; assay development; base; early phase clinical trial; genome analysis; improved; mass spectrometer; method development; patient derived xenograft model; programs; proteogenomics; repository; translational cancer research; treatment effect; tumor

The National Cancer Institute (NCI)’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. NCI supports an Antibody Program, operated by Leidos Biomedical Research, Inc (Leidos Biomed), that comprehensively characterizes affinity reagents for cancer research via the Leidos Biomed Antibody Characterization Laboratory (ACL) located at the Frederick National Laboratory for Cancer Research (FNLCR) in Frederick, MD. Within the Leidos Biomed ACL, a Proteome Characterization Laboratory (PCL) was established for comprehensive Mass Spectrometry (MS)-based proteomic characterization (global- and phospho-proteomes) and targeted (fit-for-purpose) assays. This Task Order (TO) aims not only to expand both the number of assays analyzed by the Leidos Biomed PCL, but also broadens the capabilities with method development of additional Post Translational Modifications (PTMs), fit for purpose antibodies for application such as iMRM and custom assay development. The Leidos Biomed PCL will develop and implement standardized proteomic measurements (comprehensive and targeted) for projects within CPTAC/DCTD. The Leidos Biomed PCL is equipped with two state-of-art mass spectrometers to provide the best sensitivity and accuracy for protein and peptide analysis and benchmarked for proteomic competency in coordination with CPTAC Proteome Characterization Centers (PCCs). The Leidos Biomed PCL will be available for the NCI research community to enhance translational cancer research, with priority given to CPTAC and other DCTD programs.

美国国家癌症研究所（NCI）的临床蛋白质组肿瘤分析联盟（CPTAC）是一个全国性的努力，通过大规模蛋白质组和基因组分析，或蛋白质基因组学的应用，以加速癌症的分子基础的理解。NCI支持由Leidos Biomedical Research，Inc（Leidos Biomed）运营的抗体项目，该项目通过位于Frederick，MD的Frederick国家癌症研究实验室（FNLCR）的Leidos Biomed抗体表征实验室（ACL）全面表征癌症研究的亲和试剂。在Leidos Biomed ACL内，建立了一个蛋白质组表征实验室（PCL），用于全面的基于质谱（MS）的蛋白质组表征（全局和磷酸化蛋白质组）和靶向（适用）测定。本任务指令（TO）不仅旨在扩大Leidos Biomed PCL分析的检测数量，还通过开发其他翻译后修饰（PTM）的方法扩展了能力，适用于iMRM和定制检测开发等应用的目的抗体。Leidos Biomed PCL将为CPTAC/DCTD内的项目开发和实施标准化蛋白质组学测量（全面和有针对性）。Leidos Biomed PCL配备了两台最先进的质谱仪，可为蛋白质和肽分析提供最佳的灵敏度和准确度，并与CPTAC蛋白质组表征中心（PCC）协调，以蛋白质组学能力为基准。Leidos Biomed PCL将提供给NCI研究社区，以加强转化癌症研究，优先考虑CPTAC和其他DCTD项目。